查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1766097

全球动物疫苗市场：2032 年预测 - 按类型、动物、疾病、技术、最终用户和地区进行分析

Veterinary Vaccine Market Forecasts to 2032 - Global Analysis By Type, Animal, Disease, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球动物疫苗市场预计在 2025 年达到 129.8 亿美元，预计到 2032 年将达到 219.7 亿美元，预测期内的复合年增长率为 7.8%。

兽用疫苗是生物製药，透过刺激动物免疫系统来保护动物免受某些感染疾病。疫苗含有源自病毒、细菌或寄生虫等病原体的抗原，这些抗原能够引发免疫反应，但本身并不会导致疾病。兽用疫苗是预防疾病爆发、改善动物福利和提高食品安全的重要工具。它们广泛用于家养宠物和牲畜，以减少通用感染疾病的传播，提高生产力，并减少动物健康管理中对抗生素的依赖。

根据中国国家统计局预测，2023年中国猪肉产量将达5,794万吨，比上年增加5%。

通用和感染疾病感染疾病的盛行率增加

随着动物传播给人类的疾病种类不断增加，采取预防措施保护公众健康的需求也日益增加。为了保护牲畜，避免疾病爆发造成的经济损失，畜牧生产者投入大量资金购买疫苗。为了遏止疾病传播，政府和卫生机构大力推广疫苗接种计画。新型疾病病毒株的出现进一步加剧了人们对现代先进疫苗的需求。这种紧迫感和日益增强的意识正在推动兽用疫苗产业的创新和发展。

高成本和严格的监管核准

开发创新疫苗需要在最尖端科技和专业知识方面投入大量资金。这些成本往往会延迟产品的上市，并限制规模较小的竞争对手的进入。严格的监管核准需要进行大量的安全性和有效性测试，这增加了复杂性。漫长的上市时间和冗长而昂贵的核准流程扼杀了创新。所有这些变数共同限制了全球新型动物疫苗的供应和发展。

疫苗技术和个人化医疗的进展

基于载体的疫苗接种、基于mRNA的疫苗以及重组DNA技术等技术创新，改善了免疫反应并减少了副作用。这些技术还能快速应对新出现的通用感染疾病。个人化动物照护正在推动基于动物物种、品种和健康状况的专门疫苗接种方案的需求。透过这些有针对性的策略，动物生产力和疾病预防得到了提升。总体而言，这些动态正在显着推动兽用疫苗市场的成长和相关性。

低收入地区的疫苗抗药性和有限的低温运输基础设施

文化信念、错误讯息以及对疫苗有效性的怀疑都是造成这种抵制的原因之一。此外，低温运输基础设施不足影响了疫苗的储存和运输，从而降低了疫苗的有效性。冷藏设施不足和电力供应不稳定进一步加剧了这个问题。这些问题导致疾病爆发和疫苗接种率低。因此，这些地区兽用疫苗市场的扩张和有效性持续受到限制。

COVID-19的影响

新冠疫情对兽用疫苗市场的影响不大。儘管疫情期间供应链中断和兽医就诊量减少暂时阻碍了疫苗的分销和销售，但随着宠物饲养量的增加和动物健康意识的增强，该行业已逐渐復苏。各国政府和相关人员更加重视动物疾病预防，以避免通用感染疾病的爆发，从而推动了疫苗需求。此外，疫情推动的生物技术和诊断工具的进步加速了兽用疫苗开发的创新，支持了市场復苏和长期成长。

预测期内，重组疫苗市场预计将成为最大的市场

由于更安全的疫苗接种解决方案，重组疫苗领域预计将在预测期内占据最大的市场占有率。这些疫苗降低了病原体復发的风险，并提高了动物安全性和疫苗稳定性。它们能够快速研发针对新兴疾病的疫苗，并支持及时应对疫情。它们能够高效诱导强烈的免疫反应，从而减少给药次数并提高依从性。此外，先进生物技术在动物保健领域的日益普及也推动了全球对重组疫苗的需求。

预计预测期内居家医疗领域将以最高的复合年增长率成长。

在预测期内，居家医疗领域预计将实现最高成长率，因为它能够方便及时地接种疫苗，尤其是针对伴侣动物。这减少了频繁就诊兽医的需求，使预防性医疗保健更容易获得，并减轻宠物及其饲主的压力。宠物拥有量的增加和人们对动物健康的认识不断提高，推动了家庭疫苗及相关服务的需求。使用者友善的疫苗注射系统等技术进步正在进一步促进家庭疫苗接种。这种转变将提高疫苗接种依从性，从而促进整体市场的成长。

占比最大的地区：

在预测期内，亚太地区预计将占据最大的市场占有率，这得益于牲畜存栏量的增加、人们对动物健康的认识不断提高以及政府的支持性倡议。中国、印度和澳洲等国家对口蹄疫、猪瘟和禽流感疫苗的需求正在增加。肉类和乳製品产业的扩张以及兽医基础设施的建设正在进一步推动市场发展。然而，监管壁垒和农村地区低温运输物流受限等挑战依然存在。

复合年增长率最高的地区：

预计北美地区在预测期内的复合年增长率最高。这得益于其先进的动物保健系统、强大的研发投入以及对伴侣动物健康的高度重视。美国和加拿大在创新和疫苗采用方面处于领先地位，这得益于DNA和重组疫苗等技术的广泛应用。严格的法律规范确保了疫苗质量，但同时也为新产品的进入带来了挑战。与亚太地区不同，宠物保险和兽医诊所的可及性反映了成熟的技术密集型模式，对市场动态产生了重大影响。

免费客製化服务

本报告的所有订阅者均可享有以下免费自订选项之一：

  • 公司简介
    • 对其他公司（最多 3 家）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 市场机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 企业之间的竞争

第五章。全球动物疫苗市场（按类型）

  • 灭活疫苗
  • 减毒活疫苗
  • 类毒素疫苗
  • 重组疫苗
  • DNA疫苗
  • 次单位疫苗
  • 其他类型

6. 全球动物疫苗市场（依物种）

  • 伴侣动物
    • 狗
    • 猫
  • 生产动物
    • 牛
    • 猪
    • 家禽
    • 绵羊和山羊

7. 全球动物疫苗市场（按疾病）

  • 犬瘟热
  • 狂犬病
  • 禽流感
  • 新城疫
  • 布氏桿菌症
  • 牛病毒性腹泻（BVD）
  • 其他疾病

8. 全球动物疫苗市场（依技术）

  • 常规疫苗
  • 先进疫苗

9. 全球动物疫苗市场（依最终用户）

  • 兽医诊所
  • 畜牧场
  • 居家医疗
  • 研究所
  • 其他最终用户

第十章全球动物疫苗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 合约、商业伙伴关係和合资企业
  • 企业合併与收购（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Zoetis Inc.
  • Boehringer Ingelheim GmbH
  • Merck & Co., Inc.
  • Ceva Sante Animale
  • Elanco Animal Health
  • Virbac SA
  • HIPRA
  • Phibro Animal Health Corporation
  • Vaxxinova International BV
  • Biogenesis Bago
  • Hester Biosciences Limited
  • Indian Immunologicals Ltd.
  • Neogen Corporation
  • Tianjin Ringpu Bio Technology Co., Ltd.
  • China Animal Husbandry Group
  • Jinyu Bio technology Co., Ltd.
  • Ourofino Saude Animal
  • Vetoquinol
Product Code: SMRC29953

According to Stratistics MRC, the Global Veterinary Vaccine Market is accounted for $12.98 billion in 2025 and is expected to reach $21.97 billion by 2032 growing at a CAGR of 7.8% during the forecast period. A veterinary vaccine is a biological preparation used to protect animals from specific infectious diseases by stimulating their immune systems. It contains antigens derived from pathogens such as viruses, bacteria, or parasites, which trigger an immune response without causing the disease itself. Veterinary vaccines are essential tools in preventing disease outbreaks, enhancing animal welfare, and improving food safety. They are widely used in both domestic pets and livestock to reduce the spread of zoonotic diseases, boost productivity, and decrease reliance on antibiotics in animal health management.

According to the National Bureau of Statistics China, China produced 57.94 million tonnes of pig meat in 2023, which represented a 5% increase from the previous year.

Market Dynamics:

Driver:

Rising prevalence of zoonotic diseases and livestock infections

The need for preventive measures to protect public health is growing as more diseases spread from animals to people. In order to protect animals and avoid financial losses due to disease outbreaks, livestock producers are spending money on vaccines. Vaccination programs are being promoted by governments and health organisations in an effort to curb the spread of illnesses. The need for updated and sophisticated vaccinations is further increased by the appearance of new disease strains. Innovation and growth in the veterinary vaccine sector are being driven by this increased urgency and awareness.

Restraint:

High cost and stringent regulatory approvals

Innovative vaccine development necessitates a large investment in cutting-edge technology and specialised knowledge. These costs frequently postpone product debuts and restrict access for smaller competitors. The intricacy is increased by strict regulatory approvals, which call for a great deal of safety and effectiveness testing. Time-to-market increases and innovation is discouraged by the drawn-out and expensive approval processes. All of these variables work together to limit the availability and growth of new veterinary vaccinations around the world.

Opportunity:

Advancements in vaccine technology and personalized animal care

Immune response is improved and adverse effects are decreased by innovations including vector-based vaccinations, mRNA-based vaccines, and recombinant DNA technologies. Faster reactions to newly developing zoonotic diseases are also made possible by these technologies. Demand for specialised vaccination plans based on species, breed, and health status is being driven by personalised animal care. Animal productivity and disease prevention are enhanced by this focused strategy. When taken as a whole, these dynamics greatly increase the market for veterinary vaccines' growth and relevance.

Threat:

Vaccine resistance and limited cold chain infrastructure in low-income regions

Cultural beliefs, misinformation, and doubts about the effectiveness of vaccines all play a part in this resistance. Furthermore, inadequate cold chain infrastructure compromises the effectiveness of vaccinations by affecting how they are stored and transported. The problem is made worse by inadequate refrigeration equipment and an unstable electrical supply. Disease outbreaks and vaccination coverage decline as a result of these issues. As a result, the veterinary vaccine market's expansion and efficacy in these areas continue to be limited.

Covid-19 Impact

The COVID-19 pandemic moderately impacted the Veterinary Vaccine Market. While disruptions in supply chains and reduced veterinary visits during lockdowns temporarily hindered vaccine distribution and sales, the sector rebounded as pet adoption increased and awareness of animal health grew. Governments and stakeholders emphasized disease prevention in animals to avoid zoonotic outbreaks, driving demand for vaccines. Moreover, advancements in biotechnology and diagnostic tools, inspired by the pandemic, accelerated innovation in veterinary vaccine development, supporting market recovery and long-term growth.

The recombinant vaccines segment is expected to be the largest during the forecast period

The recombinant vaccines segment is expected to account for the largest market share during the forecast period, due to safer immunization solutions. These vaccines reduce the risk of reversion to virulence, enhancing animal safety and vaccine stability. They enable rapid development against emerging diseases, supporting timely responses to outbreaks. Their efficiency in inducing strong immune responses leads to reduced dosage frequency and improved compliance. Additionally, the growing adoption of advanced biotechnology in veterinary medicine fuels the demand for recombinant vaccines globally.

The homecare settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the homecare settings segment is predicted to witness the highest growth rate by enabling convenient and timely administration of vaccines, especially for companion animals. It reduces the need for frequent veterinary clinic visits, making preventive care more accessible and less stressful for pets and owners. Growing pet ownership and increasing awareness about animal health are driving demand for home-use vaccines and related services. Technological advancements like easy-to-use vaccine delivery systems further support at-home administration. This shift enhances vaccination compliance and boosts overall market growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to increasing livestock populations, rising awareness of animal health, and supportive government initiatives. Countries like China, India, and Australia are witnessing increased demand for vaccines against foot-and-mouth disease, swine fever, and avian influenza. Expanding meat and dairy industries, along with improving veterinary infrastructure, further boost the market. However, challenges like regulatory barriers and limited cold chain logistics persist in rural areas.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced animal healthcare systems, strong R&D investments, and a high focus on companion animal health. The U.S. and Canada lead in innovation and vaccine adoption, with widespread use of technologies like DNA and recombinant vaccines. Stringent regulatory frameworks ensure vaccine quality but also pose entry challenges for new products. Unlike Asia Pacific, pet insurance and veterinary service access significantly influence market dynamics, reflecting the region's mature and technology-intensive approach.

Key players in the market

Some of the key players profiled in the Veterinary Vaccine Market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Ceva Sante Animale, Elanco Animal Health, Virbac S.A., HIPRA, Phibro Animal Health Corporation, Vaxxinova International B.V., Biogenesis Bago, Hester Biosciences Limited, Indian Immunologicals Ltd., Neogen Corporation, Tianjin Ringpu Bio-Technology Co., Ltd., China Animal Husbandry Group, Jinyu Bio-technology Co., Ltd., Ourofino Saude Animal and Vetoquinol.

Key Developments:

In June 2025, Boehringer Ingelheim entered a strategic collaboration with Eko Health, a leader in AI-powered detection of heart and lung diseases, to improve heart murmur detection in dogs. This partnership combines BI's expertise in canine cardiology with Eko's digital stethoscope and AI algorithms. The collaboration aims to launch a canine-specific heart murmur detection algorithm via an Eko mobile app in 2026, enhancing early diagnosis and care for canine heart disease.

In March 2025, Zoetis collaborated with the Federation of European Companion Animal Veterinary Associations (FECAVA) and the Federation of Veterinarians of Europe (FVE) to launch a handbook promoting best practices and policy recommendations to strengthen the human-animal bond. This initiative highlights Zoetis's commitment to advancing animal and human health through multi-stakeholder engagement.

In September 2024, Boehringer Ingelheim acquired Saiba Animal Health, a Swiss company specializing in therapeutic vaccines for companion animals. The acquisition brings SAH's virus-like particle vaccine platform into BI's R&D portfolio, targeting chronic diseases such as allergies, inflammation, and pain in pets. This move builds on previous collaborations between the companies and is expected to accelerate the development of innovative therapeutic vaccines with longer-lasting effects.

Types Covered:

  • Inactivated (Killed) Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • DNA Vaccines
  • Subunit Vaccines
  • Other Types

Animals Covered:

  • Companion Animals
  • Production Animals

Diseases Covered:

  • Canine Distemper
  • Rabies
  • Avian Influenza
  • Newcastle Disease
  • Brucellosis
  • Bovine Viral Diarrhea (BVD)
  • Other Diseases

Technologies Covered:

  • Conventional Vaccines
  • Advanced Vaccines

End Users Covered:

  • Veterinary Hospitals & Clinics
  • Livestock Farms
  • Homecare Settings
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Veterinary Vaccine Market, By Type

  • 5.1 Introduction
  • 5.2 Inactivated (Killed) Vaccines
  • 5.3 Live Attenuated Vaccines
  • 5.4 Toxoid Vaccines
  • 5.5 Recombinant Vaccines
  • 5.6 DNA Vaccines
  • 5.7 Subunit Vaccines
  • 5.8 Other Types

6 Global Veterinary Vaccine Market, By Animal

  • 6.1 Introduction
  • 6.2 Companion Animals
    • 6.2.1 Dogs
    • 6.2.2 Cats
  • 6.3 Production Animals
    • 6.3.1 Cattle
    • 6.3.2 Swine
    • 6.3.3 Poultry
    • 6.3.4 Sheep & Goats

7 Global Veterinary Vaccine Market, By Disease

  • 7.1 Introduction
  • 7.2 Canine Distemper
  • 7.3 Rabies
  • 7.4 Avian Influenza
  • 7.5 Newcastle Disease
  • 7.6 Brucellosis
  • 7.7 Bovine Viral Diarrhea (BVD)
  • 7.8 Other Diseases

8 Global Veterinary Vaccine Market, By Technology

  • 8.1 Introduction
  • 8.2 Conventional Vaccines
  • 8.3 Advanced Vaccines

9 Global Veterinary Vaccine Market, By End User

  • 9.1 Introduction
  • 9.2 Veterinary Hospitals & Clinics
  • 9.3 Livestock Farms
  • 9.4 Homecare Settings
  • 9.5 Research Institutes
  • 9.6 Other End Users

10 Global Veterinary Vaccine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Zoetis Inc.
  • 12.2 Boehringer Ingelheim GmbH
  • 12.3 Merck & Co., Inc.
  • 12.4 Ceva Sante Animale
  • 12.5 Elanco Animal Health
  • 12.6 Virbac S.A.
  • 12.7 HIPRA
  • 12.8 Phibro Animal Health Corporation
  • 12.9 Vaxxinova International B.V.
  • 12.10 Biogenesis Bago
  • 12.11 Hester Biosciences Limited
  • 12.12 Indian Immunologicals Ltd.
  • 12.13 Neogen Corporation
  • 12.14 Tianjin Ringpu Bio Technology Co., Ltd.
  • 12.15 China Animal Husbandry Group
  • 12.16 Jinyu Bio technology Co., Ltd.
  • 12.17 Ourofino Saude Animal
  • 12.18 Vetoquinol

List of Tables

  • Table 1 Global Veterinary Vaccine Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Veterinary Vaccine Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Veterinary Vaccine Market Outlook, By Inactivated (Killed) Vaccines (2024-2032) ($MN)
  • Table 4 Global Veterinary Vaccine Market Outlook, By Live Attenuated Vaccines (2024-2032) ($MN)
  • Table 5 Global Veterinary Vaccine Market Outlook, By Toxoid Vaccines (2024-2032) ($MN)
  • Table 6 Global Veterinary Vaccine Market Outlook, By Recombinant Vaccines (2024-2032) ($MN)
  • Table 7 Global Veterinary Vaccine Market Outlook, By DNA Vaccines (2024-2032) ($MN)
  • Table 8 Global Veterinary Vaccine Market Outlook, By Subunit Vaccines (2024-2032) ($MN)
  • Table 9 Global Veterinary Vaccine Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 10 Global Veterinary Vaccine Market Outlook, By Animal (2024-2032) ($MN)
  • Table 11 Global Veterinary Vaccine Market Outlook, By Companion Animals (2024-2032) ($MN)
  • Table 12 Global Veterinary Vaccine Market Outlook, By Dogs (2024-2032) ($MN)
  • Table 13 Global Veterinary Vaccine Market Outlook, By Cats (2024-2032) ($MN)
  • Table 14 Global Veterinary Vaccine Market Outlook, By Production Animals (2024-2032) ($MN)
  • Table 15 Global Veterinary Vaccine Market Outlook, By Cattle (2024-2032) ($MN)
  • Table 16 Global Veterinary Vaccine Market Outlook, By Swine (2024-2032) ($MN)
  • Table 17 Global Veterinary Vaccine Market Outlook, By Poultry (2024-2032) ($MN)
  • Table 18 Global Veterinary Vaccine Market Outlook, By Sheep & Goats (2024-2032) ($MN)
  • Table 19 Global Veterinary Vaccine Market Outlook, By Disease (2024-2032) ($MN)
  • Table 20 Global Veterinary Vaccine Market Outlook, By Canine Distemper (2024-2032) ($MN)
  • Table 21 Global Veterinary Vaccine Market Outlook, By Rabies (2024-2032) ($MN)
  • Table 22 Global Veterinary Vaccine Market Outlook, By Avian Influenza (2024-2032) ($MN)
  • Table 23 Global Veterinary Vaccine Market Outlook, By Newcastle Disease (2024-2032) ($MN)
  • Table 24 Global Veterinary Vaccine Market Outlook, By Brucellosis (2024-2032) ($MN)
  • Table 25 Global Veterinary Vaccine Market Outlook, By Bovine Viral Diarrhea (BVD) (2024-2032) ($MN)
  • Table 26 Global Veterinary Vaccine Market Outlook, By Other Diseases (2024-2032) ($MN)
  • Table 27 Global Veterinary Vaccine Market Outlook, By Technology (2024-2032) ($MN)
  • Table 28 Global Veterinary Vaccine Market Outlook, By Conventional Vaccines (2024-2032) ($MN)
  • Table 29 Global Veterinary Vaccine Market Outlook, By Advanced Vaccines (2024-2032) ($MN)
  • Table 30 Global Veterinary Vaccine Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Veterinary Vaccine Market Outlook, By Veterinary Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Veterinary Vaccine Market Outlook, By Livestock Farms (2024-2032) ($MN)
  • Table 33 Global Veterinary Vaccine Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 34 Global Veterinary Vaccine Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 35 Global Veterinary Vaccine Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.